Schrodinger Inc represents a set of core values and a strong corporate philosophy. The company focuses on delivering innovative solutions in the field of computational chemistry and advancing drug discovery and materials science. Schrodinger Inc believes in a multidisciplinary approach, combining scientific expertise with cutting-edge technology to empower researchers and accelerate scientific breakthroughs. With a commitment to collaboration, integrity, and excellence, Schrodinger Inc aims to transform the way pharmaceutical and biotechnology industries approach research and development. By harnessing the power of physics-based simulations and computational models, Schrodinger Inc strives to revolutionize drug discovery and contribute to the advancement of human health.

Schrodinger Inc is primarily present worldwide, with a strong presence in North America, Europe, and Asia. The company's global reach allows it to serve customers and collaborate with partners across borders. Schrodinger Inc's diverse international presence helps foster innovation and the development of cutting-edge computational tools for drug discovery and materials science.

Schrodinger Inc, a renowned company specializing in computational drug discovery, has achieved significant milestones since its inception. The company has developed innovative software solutions and platforms, including the widely acclaimed Schrodinger Suite, which revolutionizes drug discovery processes. Schrodinger Inc has collaborated with prominent pharmaceutical companies, accelerated drug discovery initiatives, and contributed to the development of breakthrough therapies. With its cutting-edge technologies and expertise, the company has successfully advanced multiple drug discovery programs, addressing critical diseases and meeting the evolving needs of the pharmaceutical industry. Schrodinger Inc continues to pave the way in computational chemistry, providing valuable solutions for drug designers and researchers worldwide.

Schrodinger Inc is a renowned chemical simulation and computational drug discovery company. Established in 1990, it has been a pioneer in utilizing physics-based algorithms to accelerate the discovery and development of novel drugs. With a strong focus on research and technology innovation, Schrodinger Inc has emerged as a leader in the field, providing cutting-edge solutions to leading pharmaceutical and biotechnology companies worldwide. By leveraging advanced computational techniques, including molecular dynamics simulations and quantum mechanics, the company enables scientists to gain valuable insights into drug-target interactions, leading to the identification of potential therapeutics. Schrodinger Inc's rich history and expertise make it a trusted partner in accelerating the drug discovery process.

The main competitors of Schrodinger Inc in the market are companies like OpenEye Scientific Software, BioSolveIT, and Chemical Computing Group.

Schrodinger Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Schrodinger Inc revolves around computational drug discovery. As a leading company in the field, Schrodinger Inc integrates physics-based simulations and machine learning to facilitate faster and more efficient drug development. By leveraging their innovative software platforms, such as Schrodinger Suite, the company enables biopharmaceutical companies to optimize drug discovery and development processes. Schrodinger Inc's approach allows for the generation of highly accurate computational models of drug-target interactions, aiding in the identification of promising drug candidates. With a strong focus on collaboration and scientific expertise, Schrodinger Inc continues to offer valuable solutions for the pharmaceutical industry.

Schrodinger의 P/E 비율은 -7.78입니다.

Schrodinger의 P/S 비율은 6.57입니다.

Schrodinger에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 Schrodinger 매출은 214.03 백만 USD입니다.

예상되는 Schrodinger 이익은 -180.56 백만 USD입니다.

Schrodinger Inc. is a biomedical company based in the United States that specializes in using computer simulations for the development of drugs and chemicals. The company was founded in 1990 by Dr. William L. Jorgensen and is headquartered in New York City. Schrodinger Inc.'s business model is based on the development of simulation software used to accelerate the drug development process, as well as the development of pesticides and other chemicals. The company offers software and services in the fields of medicinal chemistry, materials science, biology, and toxicology. Some of its software products include the Schrödinger Suite, a leading package for molecular simulations and modeling. In addition, the company offers a cloud-based platform called LiveDesign, which allows customers to collaborate with the Schrodinger team securely. Through this platform, users can access data and models in real-time to make faster decisions and achieve multiple goals in shorter timeframes. In the field of drug development, Schrodinger Inc. also offers compute-based services. The company provides its customers with a data-driven approach to identify drug candidates and optimize their pharmacological properties, allowing for faster identification of active ingredients and saving time and money. Additionally, Schrodinger Inc. is capable of delivering its software and services as cloud-based platforms to customers in the biotechnology industry who have limited IT resources. Customers can utilize a private cloud to host their own data and applications, gaining access to a scalable and flexible infrastructure that can quickly and efficiently respond to industry demands. With its innovative and effective technology supporting drug development, Schrodinger Inc. has established itself as a trusted provider of computer-based solutions in the pharmaceutical and biotechnology industries. With a strong focus on research and development, the company remains at the forefront of the industry and is well-positioned to continue growing and expanding.

Schrodinger은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Schrodinger의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Schrodinger의 ISIN은 US80810D1037입니다.

Schrodinger의 WKN은 A2PY7M입니다.

Schrodinger의 티커는 SDGR입니다.

지난 12개월 동안 Schrodinger은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Schrodinger은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Schrodinger의 현재 배당 수익률은 입니다.

Schrodinger은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Schrodinger은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Schrodinger은 '건강' 섹터에 속합니다.

Schrodinger의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Schrodinger는 0 USD를 배당금으로 지급했습니다.

Schrodinger의 배당금은 USD에 지급됩니다.